NGT/NFG | IFG | IGT | Diabetes | P value | |
Middle-aged group (n=2136) | |||||
N | 1022 | 418 | 466 | 230 | |
Mean age, years | 59.4±4.0 | 59.3±3.8 | 59.4±3.9 | 58.5±4.2 | 0.020 |
Female, n (%) | 623 (61) | 191 (46) | 225 (48) | 100 (43) | <0.001 |
BMI, kg/m2 | 22.0±2.6 | 23.1±2.8 | 23.6±2.9 | 24.2±3.4 | <0.001 |
Smoking | |||||
Never smoker, n (%) | 733 (72) | 266 (64) | 306 (66) | 134 (58) | <0.001 |
Current smoker, n (%) | 181 (18) | 80 (19) | 103 (22) | 68 (30) | |
Former smoker, n (%) | 108 (11) | 72 (17) | 57 (12) | 28 (12) | |
Habitual drinker, n (%) | 152 (15) | 102 (24) | 114 (24) | 51 (22) | <0.001 |
SBP, mm Hg | 119±11 | 122±11 | 122±10 | 122±10 | <0.001 |
DBP, mm Hg | 72±8 | 74±7 | 74±8 | 74±8 | <0.001 |
Fasting PG, mmol/L | 5.1±0.3 | 5.9±0.3 | 5.7±0.6 | 7.4±1.6 | <0.001 |
2-hour PG after ingestion of glucose, mmol/L | 5.8±1.1 | 6.2±1.0 | 8.9±0.9 | 14.2±4.0 | <0.001 |
Antihyperlipidemic medication, n (%) | 156 (15) | 77 (18) | 82 (18) | 36 (16) | 0.431 |
Total cholesterol, mmol/L | 5.7±0.9 | 5.7±0.9 | 5.8±0.9 | 5.8±0.9 | 0.015 |
eGFR, mL/min/1.73 m2 | 78.9±19.8 | 78.2±18.9 | 80.2±22.6 | 83.7±21.4 | 0.003 |
Follow-up period, months | 60.6±7.5 | 61.1±8.2 | 61.8±8.5 | 62.2±8.0 | 0.004 |
Elderly group (n=3426) | |||||
N | 1762 | 599 | 781 | 284 | |
Mean age, years | 70.5±4.1 | 70.6±4.1 | 70.4±4.1 | 70.2±4.2 | 0.515 |
Female, n (%) | 1134 (64) | 335 (56) | 418 (54) | 138 (49) | <0.001 |
BMI, kg/m2 | 22.1±2.8 | 23.0±3.0 | 23.3±3.1 | 23.6±3.2 | <0.001 |
Smoking, n (%) | |||||
Never smoker | 1336 (76) | 433 (72) | 530 (68) | 187 (66) | <0.001 |
Current smoker | 166 (9) | 53 (9) | 102 (13) | 50 (18) | |
Former smoker | 260 (15) | 113 (19) | 149 (19) | 47 (17) | |
Habitual drinker | 233 (13) | 110 (18) | 137 (18) | 66 (23) | <0.001 |
SBP, mm Hg | 121±11 | 124±10 | 123±10 | 123±10 | <0.001 |
DBP, mm Hg | 71±8 | 73±7 | 72±8 | 72±8 | <0.001 |
Fasting PG, mmol/L | 5.1±0.3 | 5.8±0.3 | 5.6±0.5 | 6.9±1.3 | <0.001 |
2 -hour PG after ingestion of glucose, mmol/L | 5.9±1.1 | 6.2±1.1 | 8.9±0.9 | 13.4±3.3 | <0.001 |
Antihyperlipidemic medication, n (%) | 364 (21) | 116 (19) | 170 (22) | 57 (20) | 0.739 |
Total cholesterol*, mmol/L | 5.6±0.9 | 5.7±0.9 | 5.6±0.9 | 5.7±1.0 | 0.248 |
eGFR†, mL/min/1.73 m2 | 70.6±14.6 | 70.6±17.7 | 72.9±19.3 | 73.2±18.8 | 0.070 |
Follow-up period, months | 60.3±6.9 | 60.4±7.4 | 60.3±7.1 | 61.3±7.6 | 0.179 |
Data are expressed as mean±SD or as number and percentage.
*3425 subjects.
†3426 subjects because of missing values.
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NFG, normal fasting glucose; NGT, normal glucose tolerance; PG, plasma glucose; SBP, systolic blood pressure.